腫瘤生物相似藥市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、癌症類型、配銷通路、地區和競爭細分，2019-2029F

2023 年全球腫瘤生物相似藥市場估值為32.7 億美元，預計在預測期內將穩定成長，到2029 年複合年成長率為6.84%。活力且快速發展的領域。其特點是用於治療各種癌症的生物藥物的生物相似藥的開發、批准和商業化。腫瘤生物相似藥是一種與參考生物製劑（原廠生物藥物）高度相似的生物藥物，已獲得批准並廣泛用於癌症治療。這些生物相似藥的開發目的是提供具有成本效益的替代品，同時保持與參考生物製劑相當的安全性和有效性。

市場概況
預測期	2025-2029
2023 年市場規模	32.7億美元
2029 年市場規模	47.3億美元
2024-2029 年複合年成長率	6.84%
成長最快的細分市場	肺癌
最大的市場	北美洲

主要市場促進因素

全球癌症盛行率上升

成本效益和可近性

監管支持和批准

生物技術的進步

主要市場挑戰

專利訴訟和市場獨佔性

醫生和病人的接受

主要市場趨勢

擴大腫瘤生物相似藥產品組合

免疫腫瘤藥物的生物相似藥開發

細分市場洞察

藥品類別見解

癌症洞察類型

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球腫瘤生物相似藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依藥物類別（單株抗體、G-CSF、造血劑、其他）
  • 依癌症類型（乳癌、肺癌、胃癌、攝護腺癌、子宮頸癌、血癌、腦癌、其他）
  • 依配銷通路（零售藥局、醫院藥局、網路藥局）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖

第 6 章：北美腫瘤生物相似藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 按癌症類型
  • 按配銷通路
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲腫瘤生物相似藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 按癌症類型
  • 按配銷通路
  • 按國家/地區
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太腫瘤生物相似藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 按癌症類型
  • 按配銷通路
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲腫瘤生物相似藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 按癌症類型
  • 按配銷通路
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲腫瘤生物相似藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按藥物類別
  • 按癌症類型
  • 按配銷通路
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 13 章：全球腫瘤生物相似藥市場：SWOT 分析

第14章：競爭格局

• Teva Pharmaceuticals Industries Ltd.
• STADA Arzneimittel AG
• Shanghai Henlius Biotech, Inc.
• Sandoz Group AG
• Samsung Bioepis NL BV
• Pfizer Inc.
• Ligand Pharmaceuticals Inc.
• Mylan Inc.
• Innovent Biologics (USA), Inc.
• Celltrion Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

Global Oncology Biosimilars Market was valued at USD 3.27 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.84% through 2029. The Global Oncology Biosimilars Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industry. It is characterized by the development, approval, and commercialization of biosimilar versions of biologic drugs used in the treatment of various cancers. Oncology biosimilars are biologic drugs designed to be highly similar to reference biologics (originator biologic drugs) that are already approved and widely used in cancer treatment. These biosimilars are developed to provide cost-effective alternatives while maintaining comparable safety and efficacy profiles to the reference biologics.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 3.27 Billion
Market Size 2029	USD 4.73 Billion
CAGR 2024-2029	6.84%
Fastest Growing Segment	Lung Cancer
Largest Market	North America

Key Market Drivers

Rising Prevalence of Cancer Worldwide

The escalating prevalence of cancer worldwide is a profound and multifaceted driver that significantly influences the dynamics of the Global Oncology Biosimilars Market Cancer, often referred to as the 'modern epidemic,' has seen an alarming increase in incidence rates across the globe. This surge is attributable to a multitude of factors, including lifestyle changes, aging populations, environmental factors, and genetic predispositions. The World Health Organization (WHO) estimates that cancer will become the leading cause of death worldwide in the coming years, making it imperative to find cost-effective treatment options. Cancer's prevalence extends beyond its direct impact on healthcare systems. It infiltrates economies, imposing a substantial financial burden on individuals, families, and societies. The costs associated with cancer treatment, including biologic therapies, have been a significant concern. In this context, biosimilars, with their potential for cost savings, emerge as a promising solution.

Access to cancer treatment is not uniform across regions and socioeconomic strata. Low- and middle-income countries often face challenges in providing their populations with access to the latest cancer therapies, including biologics. The rising prevalence of cancer underscores the pressing need for accessible treatment options, and biosimilars can bridge this accessibility gap by offering effective yet more affordable alternatives. The sustainability of healthcare systems is a global concern. The relentless rise in cancer incidence strains healthcare resources, necessitating innovative solutions to maintain the quality of care. Biosimilars, by reducing the financial burden of cancer treatment, can contribute to the sustainability of healthcare systems and ensure that adequate resources are allocated to cancer care without compromising other essential medical services.

Cost-Efficiency and Accessibility

Cost-efficiency and accessibility are two interrelated drivers that exert a profound influence on the Global Oncology Biosimilars Market. The synergy between these factors not only transforms the landscape of cancer treatment but also shapes the dynamics of the biosimilars market. Cancer treatments, particularly biologic therapies, are notorious for their high costs. The economic implications of cancer treatment are a cause for concern for individuals, healthcare systems, and governments alike. As cancer prevalence rises globally, the financial burden on patients and healthcare systems escalates. This financial strain creates a compelling need for cost-effective alternatives, making biosimilars an attractive solution. Cancer can be financially devastating for patients and their families. Many cancer treatments, including biologics, are prohibitively expensive, leading to significant out-of-pocket expenses. Biosimilars, designed to offer therapeutic equivalence at a lower cost, provide relief to patients by making cancer treatment more affordable and accessible. This affordability factor enhances the quality of life for patients and ensures that they have access to vital treatments.

Cost-effective biosimilars widen the spectrum of treatment options available to healthcare providers and patients. This diversity is especially critical in oncology, where treatment plans are often tailored to the individual patient's needs. Biosimilars offer a versatile toolkit for healthcare providers, enabling them to select treatments based on both clinical effectiveness and cost-efficiency. Healthcare systems worldwide are grappling with the challenge of balancing quality care with budget constraints. The introduction of biosimilars, which are typically more affordable than their reference biologics, can lead to substantial cost savings for healthcare systems. These savings can then be reinvested in improving cancer care infrastructure, research, and other essential healthcare services.

Regulatory Support and Approval

Regulatory support and approval represent a pivotal market driver in the Global Oncology Biosimilars Market. This driver plays a central role in shaping the landscape for biosimilars and influencing their widespread adoption across the healthcare industry. Regulatory bodies worldwide have established comprehensive and stringent evaluation processes for biosimilars. These processes are designed to ensure that biosimilars are equivalent to their reference biologics in terms of quality, safety, and efficacy. The rigor of these evaluations instills confidence in healthcare providers, patients, and other stakeholders regarding the reliability and effectiveness of biosimilars. One of the most striking advantages of regulatory support is the accelerated market entry it provides for biosimilars. Compared to the protracted timelines associated with the development and approval of novel biologics, biosimilars benefit from more streamlined pathways. This expedites their availability to patients in need, addressing unmet medical needs in

Regulatory backing enhances the trust and confidence of healthcare professionals in biosimilars. Physicians and clinicians are more inclined to prescribe biosimilars when they have assurance in the regulatory processes governing these products. This trust is instrumental in fostering the adoption of biosimilars as viable treatment options. Regulatory support ensures that biosimilars maintain cost-effectiveness while upholding quality and safety standards. This is of paramount importance given the financial constraints faced by healthcare systems worldwide. Biosimilars, as cost-effective alternatives to biologics, align with the goal of achieving high-value healthcare and cost containment. The regulatory environment promotes competition in the pharmaceutical market. As biosimilars gain regulatory approval, they create competition for originator biologics. This competition exerts downward pressure on the pricing of biologics, making cancer treatment more affordable for patients and healthcare systems.

Advancements in Biotechnology

The role of advancements in biotechnology as a market driver for the Global Oncology Biosimilars Market cannot be understated. These innovations are instrumental in shaping the landscape of biosimilars and their relevance in cancer treatment Advancements in biotechnology have enabled manufacturers to create biosimilars that closely resemble their reference biologics. Through improved techniques in cell line development, protein expression, and purification, biosimilars can now achieve a higher degree of similarity in terms of structure and function. This enhanced similarity reassures healthcare professionals and patients about the efficacy and safety of biosimilars. Biotechnological progress has ushered in methods to maintain the consistency and quality of biosimilars over time. This is crucial for ensuring that biosimilars consistently deliver the same therapeutic outcomes as their reference products. Patients and healthcare providers can rely on biosimilars to provide predictable and effective treatment.

Advancements in biotechnology have broadened the scope of therapeutic indications for biosimilars. Manufacturers can now explore new therapeutic areas and expand their biosimilar portfolios. In oncology, this translates to an increasing number of treatment options for various types of cancers, catering to a wider patient population. Biotechnological innovations have led to more efficient and scalable manufacturing processes for biosimilars. This translates to increased production capacity and cost-effectiveness. As a result, biosimilars become more accessible and affordable, addressing the economic burden associated with cancer treatment.

Key Market Challenges

Patent Litigation and Market Exclusivity

Originator biologic manufacturers often resort to patent litigation to extend their market exclusivity. These legal battles can delay the entry of biosimilars into the market. The complex nature of biologics patents can lead to protracted legal disputes. Regulatory authorities may grant exclusivity extensions to reference biologics for various reasons, such as pediatric indications or orphan drug status. These extensions can further delay biosimilar market entry, limiting competition. The legal and regulatory costs associated with biosimilar development and patent litigation can be substantial. Smaller manufacturers may find it challenging to navigate these hurdles, potentially slowing down their entry into the market.

Physician and Patient Acceptance

Physicians and patients may have limited familiarity with biosimilars compared to reference biologics. This lack of awareness can lead to hesitancy in adopting biosimilars in oncology practice. Despite regulatory assurances of biosimilarity, some healthcare professionals and patients may perceive differences between biosimilars and reference biologics. This perception can create resistance to adopting biosimilars in cancer treatment. Effective education and communication about the safety and efficacy of biosimilars are essential. Not all healthcare systems invest in comprehensive educational initiatives, which can hinder adoption.

Key Market Trends

Expanding Oncology Biosimilar Portfolio

The oncology biosimilars market is witnessing an expansion of biosimilar offerings targeting a wide range of cancer types. Initially focused on breast cancer and hematologic malignancies, biosimilar manufacturers are now developing products for lung, colorectal, and gastric cancers, among others. This trend diversifies treatment options for cancer patients. Notable reference biologics in oncology, such as trastuzumab (Herceptin) and bevacizumab (Avastin), have attracted multiple biosimilar developers. This competition leads to a variety of biosimilar options for healthcare providers, promoting cost savings and enhancing access to treatment. Monoclonal antibodies represent a significant portion of oncology biologics. Biosimilar development in this category is booming, with the introduction of biosimilars for rituximab (Rituxan), cetuximab (Erbitux), and other monoclonal antibodies. These biosimilars are poised to revolutionize the treatment landscape.

Biosimilar Development for Immuno-Oncology Agents

Immuno-oncology has transformed cancer treatment paradigms. Biosimilar developers are now targeting immuno-oncology agents, including checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo). These biosimilars have the potential to offer cost-effective alternatives in a rapidly evolving therapeutic area. Immuno-oncology biologics are complex and costly. Biosimilars for these agents have the potential to generate substantial cost savings, making them an attractive proposition for both healthcare systems and patients. Biosimilar developers are focusing on the global market for oncology biosimilars. Expanding their reach beyond local or regional markets, manufacturers are seeking approvals in multiple countries to maximize their impact on cancer treatment worldwide.

Segmental Insights

Drug Class Insights

Based on Drug Class, Monoclonal Antibodies have emerged as the dominating segment in the global market for oncology biosimilars in 2023. Monoclonal antibodies are engineered to precisely target cancer cells or proteins implicated in cancer progression. This precise targeting minimizes adverse effects compared to conventional chemotherapy, making them attractive to both patients and healthcare providers. Numerous monoclonal antibodies have shown notable effectiveness across various cancer types by specifically binding to cancer cells and disrupting their growth or survival mechanisms, leading to enhanced patient outcomes in clinical trials. Biosimilars, which are biological products highly resembling an already approved reference biologic, exhibit no clinically significant disparities in safety, efficacy, or quality. Monoclonal antibodies are particularly suitable for biosimilar development due to their intricate structures replicable through advanced biotechnological methodologies.

Type of Cancer Insight

Based on Type of Cancer, Lung Cancer have emerged as the fastest growing segment in the Global Oncology Biosimilars Market in 2023. Lung cancer's dominance within the global oncology biosimilars market is a multifaceted phenomenon driven by several interrelated factors. The sheer prevalence of lung cancer on a global scale significantly influences the demand for effective and affordable treatment options. Lung cancer ranks among the most commonly diagnosed cancers worldwide, with its incidence steadily rising in many regions. This high prevalence necessitates a robust market for therapies, including biosimilars, which offer comparable efficacy to biologics but at potentially lower costs. The complex nature of lung cancer necessitates multimodal treatment approaches, often combining surgery, chemotherapy, radiation therapy, and targeted therapies. This complexity underscores the need for a diverse range of treatment options, including biosimilars, to address various stages and types of lung cancer comprehensively. The regulatory support and patent expirations play a crucial role in fostering biosimilar development and market penetration. Regulatory agencies worldwide have been increasingly supportive of biosimilar approval pathways, streamlining the process for manufacturers to bring these cost-effective alternatives to market. As patents for existing biologics used in lung cancer treatment expire, it creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, driving competition and potentially lowering prices.

Regional Insights

Based on region, North America have emerged as the dominating region in the Global Oncology Biosimilars Market primarily due to several key factors. The region is home to a high incidence rate of cancer, which drives the demand for affordable treatment options like biosimilars. The presence of leading pharmaceutical companies promoting research and development of biosimilars, coupled with the robust healthcare infrastructure and favorable government policies, further contribute to the market growth. The acceptance of biosimilars as a cost-effective alternative to high-priced patented drugs has also been on a steady rise, bolstering the market's expansion in North America. The high prevalence of cancer in North America has also led to a significant demand for biosimilars in the region. With an aging population and increasing cases of chronic diseases, there is a growing need for affordable treatment options, which has further accelerated the adoption of biosimilars.

Key Market Players

Teva Pharmaceuticals Industries Ltd.

STADA Arzneimittel AG

Shanghai Henlius Biotech, Inc.

Sandoz Group AG

Samsung Bioepis NL B.V.

Pfizer Inc.

Ligand Pharmaceuticals Inc.

Mylan Inc.

Innovent Biologics (USA), Inc.

Celltrion Inc.

Report Scope:

In this report, the Global Oncology Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Biosimilars Market, By Drug Class:

Monoclonal Antibodies G-CSF Hematopoietic Agents Others

Oncology Biosimilars Market, By Type of Cancer:

Breast Cancer Lung Cancer Stomach Cancer Prostate Cancer Cervical Cancer Blood Cancer Brain Cancer Others

Oncology Biosimilars Market, By Distribution Channel:

Retail Pharmacies Hospital Pharmacies Online Pharmacies

Oncology Biosimilars Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Biosimilars Market.

Available Customizations:

Global Oncology Biosimilars Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Biosimilars Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others)
  • 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map

6. North America Oncology Biosimilars Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Type of Cancer
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oncology Biosimilars Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Type of Cancer
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Oncology Biosimilars Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Type of Cancer
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Oncology Biosimilars Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Type of Cancer
      • 6.3.3.2.3. By Distribution Channel

7. Europe Oncology Biosimilars Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type of Cancer
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oncology Biosimilars Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Type of Cancer
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Oncology Biosimilars Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Type of Cancer
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Oncology Biosimilars Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Type of Cancer
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Oncology Biosimilars Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Type of Cancer
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Oncology Biosimilars Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Type of Cancer
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Oncology Biosimilars Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type of Cancer
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oncology Biosimilars Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Type of Cancer
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Oncology Biosimilars Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Type of Cancer
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Oncology Biosimilars Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type of Cancer
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Oncology Biosimilars Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Type of Cancer
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Oncology Biosimilars Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Type of Cancer
      • 8.3.5.2.3. By Distribution Channel

9. South America Oncology Biosimilars Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Type of Cancer
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oncology Biosimilars Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Type of Cancer
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Oncology Biosimilars Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Type of Cancer
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Oncology Biosimilars Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Type of Cancer
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Oncology Biosimilars Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Type of Cancer
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oncology Biosimilars Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Type of Cancer
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Oncology Biosimilars Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Type of Cancer
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Oncology Biosimilars Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Type of Cancer
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Oncology Biosimilars Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Teva Pharmaceuticals Industries Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. STADA Arzneimittel AG
• 14.3. Shanghai Henlius Biotech, Inc.
• 14.4. Sandoz Group AG
• 14.5. Samsung Bioepis NL B.V.
• 14.6. Pfizer Inc.
• 14.7. Ligand Pharmaceuticals Inc.
• 14.8. Mylan Inc.
• 14.9. Innovent Biologics (USA), Inc.
• 14.10. Celltrion Inc.

15. Strategic Recommendations

16. About Us & Disclaimer